In a prospective, multicenter, open-label study, de novo liver transplant patients were randomized at day 30±5 to (i) everolimus initiation with tacrolimus elimination (TAC Elimination) (ii) everolimus initiation with reduced-exposure tacrolimus (EVR+Reduced TAC) or (iii) standard-exposure tacrolimus (TAC Control). Randomization to TAC Elimination was terminated prematurely due to a higher rate of treated biopsy-proven acute rejection (tBPAR). EVR+Reduced TAC was noninferior to TAC Control for the primary efficacy endpoint (tBPAR, graft loss or death at 12 months posttransplantation): 6.7% versus 9.7% (-3.0%; 95% CI -8.7, 2.6%; p<0.001 for noninferiority [12% margin]). tBPAR occurred in 2.9% of EVR+Reduced TAC patients versus 7.0% of TAC Controls (p = 0.035). The change in adjusted estimated GFR from randomization to month 12 was superior with EVR+Reduced TAC versus TAC Control (difference 8.50 mL/min/1.73 m2, 97.5% CI 3.74, 13.27 mL/min/1.73 m2, p<0.001 for superiority). Drug discontinuation for adverse events occurred in 25.7% of EVR+Reduced TAC and 14.1% of TAC Controls (relative risk 1.82, 95% CI 1.25, 2.66). Relative risk of serious infections between the EVR+Reduced TAC group versus TAC Controls was 1.76 (95% CI 1.03, 3.00). Everolimus facilitates early tacrolimus minimization with comparable efficacy and superior renal function, compared to a standard tacrolimus exposure regimen 12 months after liver transplantation. © Copyright 2012 The American Society of Transplantation and the American Society of Transplant Surgeons.

De Simone, P., Nevens, F., DE CARLIS, L., Metselaar, H., Beckebaum, S., Saliba, F., et al. (2012). Everolimus with reduced tacrolimus improves renal function in de novo liver transplant recipients: A randomized controlled trial. AMERICAN JOURNAL OF TRANSPLANTATION, 12(11), 3008-3020 [10.1111/j.1600-6143.2012.04212.x].

Everolimus with reduced tacrolimus improves renal function in de novo liver transplant recipients: A randomized controlled trial

DE CARLIS, LUCIANO GREGORIO;
2012

Abstract

In a prospective, multicenter, open-label study, de novo liver transplant patients were randomized at day 30±5 to (i) everolimus initiation with tacrolimus elimination (TAC Elimination) (ii) everolimus initiation with reduced-exposure tacrolimus (EVR+Reduced TAC) or (iii) standard-exposure tacrolimus (TAC Control). Randomization to TAC Elimination was terminated prematurely due to a higher rate of treated biopsy-proven acute rejection (tBPAR). EVR+Reduced TAC was noninferior to TAC Control for the primary efficacy endpoint (tBPAR, graft loss or death at 12 months posttransplantation): 6.7% versus 9.7% (-3.0%; 95% CI -8.7, 2.6%; p<0.001 for noninferiority [12% margin]). tBPAR occurred in 2.9% of EVR+Reduced TAC patients versus 7.0% of TAC Controls (p = 0.035). The change in adjusted estimated GFR from randomization to month 12 was superior with EVR+Reduced TAC versus TAC Control (difference 8.50 mL/min/1.73 m2, 97.5% CI 3.74, 13.27 mL/min/1.73 m2, p<0.001 for superiority). Drug discontinuation for adverse events occurred in 25.7% of EVR+Reduced TAC and 14.1% of TAC Controls (relative risk 1.82, 95% CI 1.25, 2.66). Relative risk of serious infections between the EVR+Reduced TAC group versus TAC Controls was 1.76 (95% CI 1.03, 3.00). Everolimus facilitates early tacrolimus minimization with comparable efficacy and superior renal function, compared to a standard tacrolimus exposure regimen 12 months after liver transplantation. © Copyright 2012 The American Society of Transplantation and the American Society of Transplant Surgeons.
Articolo in rivista - Articolo scientifico
Efficacy; everolimus; liver transplantation; reduced; tacrolimus; withdrawal; Adolescent; Adult; Aged; Confidence Intervals; Cross-Over Studies; Dose-Response Relationship, Drug; Drug Administration Schedule; Everolimus; Follow-Up Studies; Glomerular Filtration Rate; Graft Rejection; Graft Survival; Humans; Immunosuppressive Agents; Kaplan-Meier Estimate; Kidney; Kidney Function Tests; Liver Failure; Liver Transplantation; Male; Middle Aged; Prospective Studies; Risk Assessment; Sirolimus; Survival Analysis; Tacrolimus; Time Factors; Transplantation Immunology; Treatment Outcome; Young Adult; Transplantation; Immunology and Allergy; Pharmacology (medical)
English
3008
3020
13
De Simone, P., Nevens, F., DE CARLIS, L., Metselaar, H., Beckebaum, S., Saliba, F., et al. (2012). Everolimus with reduced tacrolimus improves renal function in de novo liver transplant recipients: A randomized controlled trial. AMERICAN JOURNAL OF TRANSPLANTATION, 12(11), 3008-3020 [10.1111/j.1600-6143.2012.04212.x].
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10281/101033
Citazioni
  • Scopus 232
  • ???jsp.display-item.citation.isi??? 226
Social impact